Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approvals from the U.S. FDA for its ANDAs for Mycophenolate Mofetil Tablets, 500 mg, and Mycophenolate Mofetil Capsules, 250 mg.